Literature DB >> 20810726

Cytopathogenesis of Sendai virus in well-differentiated primary pediatric bronchial epithelial cells.

Rémi Villenave1, Olivier Touzelet, Surendran Thavagnanam, Severine Sarlang, Jeremy Parker, Grzegorz Skibinski, Liam G Heaney, James P McKaigue, Peter V Coyle, Michael D Shields, Ultan F Power.   

Abstract

Sendai virus (SeV) is a murine respiratory virus of considerable interest as a gene therapy or vaccine vector, as it is considered nonpathogenic in humans. However, little is known about its interaction with the human respiratory tract. To address this, we developed a model of respiratory virus infection based on well-differentiated primary pediatric bronchial epithelial cells (WD-PBECs). These physiologically authentic cultures are comprised of polarized pseudostratified multilayered epithelium containing ciliated, goblet, and basal cells and intact tight junctions. To facilitate our studies, we rescued a replication-competent recombinant SeV expressing enhanced green fluorescent protein (rSeV/eGFP). rSeV/eGFP infected WD-PBECs efficiently and progressively and was restricted to ciliated and nonciliated cells, not goblet cells, on the apical surface. Considerable cytopathology was evident in the rSeV/eGFP-infected cultures postinfection. This manifested itself by ciliostasis, cell sloughing, apoptosis, and extensive degeneration of WD-PBEC cultures. Syncytia were also evident, along with significant basolateral secretion of proinflammatory chemokines, including IP-10, RANTES, tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), interleukin 6 (IL-6), and IL-8. Such deleterious responses are difficult to reconcile with a lack of pathogenesis in humans and suggest that caution may be required in exploiting replication-competent SeV as a vaccine vector. Alternatively, such robust responses might constitute appropriate normal host responses to viral infection and be a prerequisite for the induction of efficient immune responses.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20810726      PMCID: PMC2977906          DOI: 10.1128/JVI.00798-10

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  46 in total

Review 1.  Reverse genetics of mononegavirales.

Authors:  K K Conzelmann
Journal:  Curr Top Microbiol Immunol       Date:  2004       Impact factor: 4.291

2.  Recombinant Sendai virus for efficient gene transfer to human airway epithelium.

Authors:  Olaf Pinkenburg; Claus Vogelmeier; Sascha Bossow; Wolfgang J Neubert; Raimund B Lutz; Guy Ungerechts; Ulrich M Lauer; Michael Bitzer; Robert Bals
Journal:  Exp Lung Res       Date:  2004-03       Impact factor: 2.459

3.  Longer and shorter forms of Sendai virus C proteins play different roles in modulating the cellular antiviral response.

Authors:  D Garcin; J Curran; M Itoh; D Kolakofsky
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

4.  Identification of biological activities of paramyxovirus glycoproteins. Activation of cell fusion, hemolysis, and infectivity of proteolytic cleavage of an inactive precursor protein of Sendai virus.

Authors:  A Scheid; P W Choppin
Journal:  Virology       Date:  1974-02       Impact factor: 3.616

5.  Trypsin action on the growth of Sendai virus in tissue culture cells. I. Restoration of the infectivity for L cells by direct action of tyrpsin on L cell-borne Sendai virus.

Authors:  M Homma
Journal:  J Virol       Date:  1971-11       Impact factor: 5.103

6.  Negative-strand RNA viral vectors: intravenous application of Sendai virus vectors for the systemic delivery of therapeutic genes.

Authors:  Michael Bitzer; Guy Ungerechts; Sascha Bossow; Florian Graepler; Reinhard Sedlmeier; Sorin Armeanu; Christian Bernloehr; Martin Spiegel; Christine D Gross; Michael Gregor; Wolfgang J Neubert; Ulrich M Lauer
Journal:  Mol Ther       Date:  2003-02       Impact factor: 11.454

7.  A defective nontransmissible recombinant Sendai virus mediates efficient gene transfer to airway epithelium in vivo.

Authors:  S Ferrari; U Griesenbach; T Shiraki-Iida; T Shu; T Hironaka; X Hou; J Williams; J Zhu; P K Jeffery; D M Geddes; M Hasegawa; E W F W Alton
Journal:  Gene Ther       Date:  2004-11       Impact factor: 5.250

8.  Characterization of the amino acid residues of sendai virus C protein that are critically involved in its interferon antagonism and RNA synthesis down-regulation.

Authors:  Atsushi Kato; Case Cortese-Grogan; Sue A Moyer; Fumihiro Sugahara; Takemasa Sakaguchi; Toru Kubota; Noriyuki Otsuki; Masayoshi Kohase; Masato Tashiro; Yoshiyuki Nagai
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

9.  The effect of respiratory synctial virus on chemokine release by differentiated airway epithelium.

Authors:  Thomas E Mellow; Paula C Murphy; Johnny L Carson; Terry L Noah; Liqun Zhang; Raymond J Pickles
Journal:  Exp Lung Res       Date:  2004 Jan-Feb       Impact factor: 2.459

10.  Safety and immunogenicity of intranasal murine parainfluenza virus type 1 (Sendai virus) in healthy human adults.

Authors:  Karen S Slobod; Jerry L Shenep; Jorge Luján-Zilbermann; Kim Allison; Brita Brown; Ruth Ann Scroggs; Allen Portner; Chris Coleclough; Julia L Hurwitz
Journal:  Vaccine       Date:  2004-08-13       Impact factor: 3.641

View more
  17 in total

1.  Comparative Therapeutic Potential of ALX-0171 and Palivizumab against Respiratory Syncytial Virus Clinical Isolate Infection of Well-Differentiated Primary Pediatric Bronchial Epithelial Cell Cultures.

Authors:  Lindsay Broadbent; Hong Guo Parke; Lyndsey J Ferguson; Andrena Millar; Michael D Shields; Laurent Detalle; Ultan F Power
Journal:  Antimicrob Agents Chemother       Date:  2020-01-27       Impact factor: 5.191

2.  The Nectin-4/Afadin Protein Complex and Intercellular Membrane Pores Contribute to Rapid Spread of Measles Virus in Primary Human Airway Epithelia.

Authors:  Brajesh K Singh; Andrew L Hornick; Sateesh Krishnamurthy; Anna C Locke; Crystal A Mendoza; Mathieu Mateo; Catherine L Miller-Hunt; Roberto Cattaneo; Patrick L Sinn
Journal:  J Virol       Date:  2015-04-29       Impact factor: 5.103

3.  Induction and Antagonism of Antiviral Responses in Respiratory Syncytial Virus-Infected Pediatric Airway Epithelium.

Authors:  Rémi Villenave; Lindsay Broadbent; Isobel Douglas; Jeremy D Lyons; Peter V Coyle; Michael N Teng; Ralph A Tripp; Liam G Heaney; Michael D Shields; Ultan F Power
Journal:  J Virol       Date:  2015-09-30       Impact factor: 5.103

4.  Characterization of the interaction between human respiratory syncytial virus and the cell cycle in continuous cell culture and primary human airway epithelial cells.

Authors:  Weining Wu; Diane C Munday; Gareth Howell; Gareth Platt; John N Barr; Julian A Hiscox
Journal:  J Virol       Date:  2011-07-27       Impact factor: 5.103

5.  In vitro modeling of respiratory syncytial virus infection of pediatric bronchial epithelium, the primary target of infection in vivo.

Authors:  Rémi Villenave; Surendran Thavagnanam; Severine Sarlang; Jeremy Parker; Isobel Douglas; Grzegorz Skibinski; Liam G Heaney; James P McKaigue; Peter V Coyle; Michael D Shields; Ultan F Power
Journal:  Proc Natl Acad Sci U S A       Date:  2012-03-12       Impact factor: 11.205

6.  A Respiratory Syncytial Virus Vaccine Vectored by a Stable Chimeric and Replication-Deficient Sendai Virus Protects Mice without Inducing Enhanced Disease.

Authors:  Marian Alexander Wiegand; Gianni Gori-Savellini; Claudia Gandolfo; Guido Papa; Christine Kaufmann; Eva Felder; Alessandro Ginori; Maria Giulia Disanto; Donatella Spina; Maria Grazia Cusi
Journal:  J Virol       Date:  2017-04-28       Impact factor: 5.103

7.  Expression of dermcidin in human sinonasal secretions.

Authors:  Elizabeth E Cottrill; Bei Chen; Nithin D Adappa; James N Palmer; David W Kennedy; Robert J Lee; Noam A Cohen
Journal:  Int Forum Allergy Rhinol       Date:  2016-09-21       Impact factor: 3.858

8.  Conditional reprogramming of pediatric airway epithelial cells: A new human model to investigate early-life respiratory disorders.

Authors:  S Wolf; G F Perez; L Mukharesh; N Isaza; D Preciado; R J Freishtat; D Pillai; M C Rose; G Nino
Journal:  Pediatr Allergy Immunol       Date:  2017-11-22       Impact factor: 6.377

9.  The respiratory syncytial virus fusion protein and neutrophils mediate the airway mucin response to pathogenic respiratory syncytial virus infection.

Authors:  Kate L Stokes; Michael G Currier; Kaori Sakamoto; Sujin Lee; Peter L Collins; Richard K Plemper; Martin L Moore
Journal:  J Virol       Date:  2013-07-10       Impact factor: 5.103

10.  Long-term IL-33-producing epithelial progenitor cells in chronic obstructive lung disease.

Authors:  Derek E Byers; Jennifer Alexander-Brett; Anand C Patel; Eugene Agapov; Geoffrey Dang-Vu; Xiaohua Jin; Kangyun Wu; Yingjian You; Yael Alevy; Jean-Philippe Girard; Thaddeus S Stappenbeck; G Alexander Patterson; Richard A Pierce; Steven L Brody; Michael J Holtzman
Journal:  J Clin Invest       Date:  2013-08-15       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.